Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Blinded, Sham Procedure-Controlled, Parallel-Group Trial to Evaluate the Efficacy, Safety and Tolerability of LYR-210 in Adult Subjects With Chronic Sinusitis (LANTERN Study)

NCT04041609 is registered in ClinicalTrials.gov with Lyra Therapeutics as lead sponsor.

NCT NCT04041609
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04041609 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Blinded, Sham Procedure-Controlled, Parallel-Group Trial to Evaluate the Efficacy, Safety and Tolerability of LYR-210 in Adult Subjects With Chronic Sinusitis (LANTERN Study)
Lead sponsor
Lyra Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
May 9, 2019
Completion date
February 4, 2021
Enrollment
71 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

chronic rhinosinusitis (diagnosis), chronic sinusitis